https://www.bioworld.com/rss en-us Artan Biotechnologies LLC has completed a $200,000 seed raise to fund preclinical advancement of the company’s proprietary engineered suppressor platform, which targets nonsense mutations. http://www.bioworld.com/articles/731677 Fri, 05 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731677-seed-funding-at-artan-bio-supports-work-on-aging Woman and molecular overlay Daewoong Pharmaceutical Co. Ltd. announced after South Korean market hours May 21 that it gained successive rights to Turn Biotechnologies Inc.’s mRNA-based cellular rejuvenation platform from Hanall Biopharma Co. Ltd. http://www.bioworld.com/articles/731469 Tue, 26 May 2026 11:00:00 -0400 https://www.bioworld.com/articles/731469-daewoong-takes-over-turn-bios-longevity-platform-from-hanall DNA double helix with sand hour glass Daewoong Pharmaceutical Co. Ltd. announced after South Korean market hours May 21 that it gained successive rights to Turn Biotechnologies Inc.’s mRNA-based cellular rejuvenation platform from Hanall Biopharma Co. Ltd. http://www.bioworld.com/articles/731389 Fri, 22 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731389-daewoong-takes-over-turn-bios-longevity-platform-from-hanall DNA double helix with sand hour glass WAVES, an algorithm designed to extract menstrual-cycle metrics from physiological signals such as basal body temperature, which oscillates with sex hormones, shows how different parameters change with age and helps determine whether each person maintains a stable individual pattern or personal footprint. A study based on data from 5,674 cycles from 753 women demonstrates through this tool that age is associated with higher temperatures, shorter cycles, and greater irregularity. In addition, several metrics show within-person stability, suggesting they could serve as personalized health markers. http://www.bioworld.com/articles/731248 Fri, 22 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731248-menstrual-footprints-may-act-as-broad-personal-health-markers Female uterus and ovaries on abstract scientific background Armed with a fully subscribed $80 million series D round, Life Biosciences Inc. is making progress with its lead candidate, ER-100, which is in phase I trials testing its theory on reversing the biological effects of aging via partial epigenetic reprogramming. http://www.bioworld.com/articles/730208 Thu, 09 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730208-with-80m-series-d-life-biosciences-advances-epigenetic-reprogramming Illustration of double helix Werner syndrome results from biallelic mutations in the WRN gene on chromosome 8, leading to accelerated aging symptoms. Researchers at Sumitomo Pharma Co. Ltd. have reported the development and characterization of WRN-108, a splice-switching antisense oligonucleotide (ASO) designed to induce exon 27 skipping in WRN transcripts carrying the c.3139-1G>C mutation. C mutation.]]> http://www.bioworld.com/articles/730187 Wed, 08 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730187-topical-aso-restores-wrn-function-for-chronic-skin-ulcers-in-werner-syndrome Missing puzzle piece and broken DNA chain Deep molecular advances are enabling precision medicine for the field of hematology, Wyndham Wilson said during a plenary session at the 2026 Korean Society of Hematology International Conference March 26. http://www.bioworld.com/articles/730204 Tue, 07 Apr 2026 11:00:00 -0400 https://www.bioworld.com/articles/730204-five-drug-vipor-regimen-shows-promise-in-aggressive-blood-cancer PET scans showing before and after treatment with VIPOR Before (top) and after (bottom) treatment with VIPOR. Full-body and cross-sectional PET scans of a patient show large lymphoma tumors (circled in red) that have disappeared with treatment. Credit: Center for Cancer Research/National Cancer Institute Deep molecular advances are enabling precision medicine for the field of hematology, Wyndham Wilson said during a plenary session at the 2026 Korean Society of Hematology International Conference March 26. http://www.bioworld.com/articles/729980 Wed, 01 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/729980-five-drug-vipor-regimen-shows-promise-in-aggressive-blood-cancer PET scans showing before and after treatment with VIPOR Before (top) and after (bottom) treatment with VIPOR. Full-body and cross-sectional PET scans of a patient show large lymphoma tumors (circled in red) that have disappeared with treatment. Credit: Center for Cancer Research/National Cancer Institute Braveheart Bio Inc. reported positive results from an open-label randomized phase II dose-ranging study of BHB-1893 (HRS-1893) in obstructive hypertrophic cardiomyopathy. Results presented at the American College of Cardiology’s Annual Scientific Session and Expo in New Orleans showed BHB-1893 treatment was associated with rapid and substantial reductions in left ventricular outflow tract gradient, the primary endpoint of the study. http://www.bioworld.com/articles/729968 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729968-braveheart-finds-phase-ii-positive-for-cardiac-myosin-inhibitor 3D illustration of heart cross section Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). At the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), scientists focused on TREM2, a microglial receptor that regulates immune responses, exploring new ways to address neuroinflammation. http://www.bioworld.com/articles/730054 Fri, 27 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/730054-small-molecule-trem2-agonist-advances-to-treat-alzheimers Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to damage signals such as amyloid accumulation. When the process starts, the initial microglial response can be protective. However, in later stages, this response becomes dysfunctional and contributes to disease progression. At the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), scientists focused on TREM2, a microglial receptor that regulates immune responses, exploring new ways to address neuroinflammation. http://www.bioworld.com/articles/729927 Thu, 26 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729927-small-molecule-trem2-agonist-advances-to-treat-alzheimers Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the abnormal accumulation of α-synuclein, a protein that forms toxic aggregates and spreads between cells, damaging them. At the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), held from March 17 to 21, 2026, in Copenhagen, several strategies were presented that aim to modify the course of the disease and offer real alternatives to purely symptomatic treatments. http://www.bioworld.com/articles/729789 Mon, 23 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729789-emerging-therapeutic-strategies-for-parkinsons-at-adpd-2026 Art concept for Parkinson's disease A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change how new drugs are developed to achieve more effective therapies. This new perspective could rethink strategies that depend not so much on the target itself, but on the precise moment at which it is addressed. http://www.bioworld.com/articles/729852 Fri, 20 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729852-adpd-2026-three-inflection-points-to-target-alzheimers-disease Illustration of Alzheimer's disease in the brain A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change how new drugs are developed to achieve more effective therapies. This new perspective could rethink strategies that depend not so much on the target itself, but on the precise moment at which it is addressed. http://www.bioworld.com/articles/729719 Thu, 19 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729719-adpd-2026-three-inflection-points-to-target-alzheimers-disease Illustration of Alzheimer's disease in the brain Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated microglia and astrocytes, altered receptors such as TREM2, mitochondrial dysfunction, epigenetic changes and cerebrovascular alterations all seem to contribute to the development of dementia in Alzheimer’s disease (AD). While scientists attempt to address each of these elements, prevention is growing as a primary goal. http://www.bioworld.com/articles/729688 Wed, 18 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729688-adpd-2026-can-we-prevent-dementia-scientists-quantify-it MRI image brain on black background Two biotech and three med-tech companies are slated for Kosdaq debuts this month, signaling a potential rebound for Korea financings in 2026. Kanaph Therapeutics Inc. will open with a ₩40 billion (US$26.99 million) raise and Imbiologics Corp. will debut with ₩52 billion. Additionally, Mezoo Co. Ltd., Cosmo Robotics Co. Ltd. and Recensmedical Inc. will launch IPOs. http://www.bioworld.com/articles/729714 Tue, 17 Mar 2026 11:00:00 -0400 https://www.bioworld.com/articles/729714-kanaph-imbiologics-to-kick-off-2026-korea-biotech-med-tech-ipos Ha Gyong sik giving a presentation Ha Gyong-sik, CEO, Imbiologics Two biotech and three med-tech companies are slated for Kosdaq debuts this month, signaling a potential rebound for Korea financings in 2026. Kanaph Therapeutics Inc. will open with a ₩40 billion (US$26.99 million) raise and Imbiologics Corp. will debut with ₩52 billion. Additionally, Mezoo Co. Ltd., Cosmo Robotics Co. Ltd. and Recensmedical Inc. will launch IPOs. http://www.bioworld.com/articles/729495 Fri, 13 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729495-kanaph-imbiologics-to-kick-off-2026-korea-biotech-med-tech-ipos Ha Gyong sik giving a presentation Ha Gyong-sik, CEO, Imbiologics The K-health MIRAE Initiative, also known as Korean ARPA-H, announced plans to allocate about ₩162 billion (US$110 million) in nine new projects over the next five years, with a focus on strengthening national health security. http://www.bioworld.com/articles/729582 Tue, 10 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729582-korean-arpa-h-to-invest-162b-in-nine-projects-in-2026 Korea ARPA-H roundtable K-health MIRAE Initiative Director General Sun Kyung, center, and project managers at a roundtable meeting in Seoul, South Korea on March 5. Taiwan plans to invest NT$24 billion (US$752 million) over four years to bolster national biosecurity, expand domestic pharmaceutical production and safeguard against global supply chain volatility. http://www.bioworld.com/articles/729579 Tue, 10 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729579-taiwan-to-invest-752m-in-biopharma-security-over-four-years Taiwan President Lai Ching-te presides over the seventh meeting of the Healthy Taiwan Promotion Committee. Taiwan President Lai Ching-te, center, presides over the seventh meeting of the Healthy Taiwan Promotion Committee. If one could sweep the brain clean and send the toxic substances that drive neurodegeneration to the recycling bin, perhaps one could treat Alzheimer’s disease. Researchers at the Chinese Academy of Sciences propose a new therapeutic strategy that uses synthetic peptides that bind to amyloid-β (Aβ) and direct it toward lysosomes. In addition, researchers at the Washington University School of Medicine in St. Louis have genetically modified astrocytes in vivo to express chimeric antigen receptors (CARs) that recognize and phagocytose Aβ plaques. http://www.bioworld.com/articles/729577 Tue, 10 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729577-synthetic-peptide-and-car-a-each-clear-amyloid-in-alzheimers Illustration of amyloid plaques on neurons Taiwan plans to invest NT$24 billion (US$752 million) over four years to bolster national biosecurity, expand domestic pharmaceutical production and safeguard against global supply chain volatility. http://www.bioworld.com/articles/729440 Mon, 09 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729440-taiwan-to-invest-752m-in-biopharma-security-over-four-years Taiwan President Lai Ching-te presides over the seventh meeting of the Healthy Taiwan Promotion Committee. Taiwan President Lai Ching-te, center, presides over the seventh meeting of the Healthy Taiwan Promotion Committee. If one could sweep the brain clean and send the toxic substances that drive neurodegeneration to the recycling bin, perhaps one could treat Alzheimer’s disease (AD). Researchers at the Chinese Academy of Sciences propose a new therapeutic strategy that uses synthetic peptides that bind to amyloid-β (Aβ) and direct it toward lysosomes. In addition, researchers at the Washington University School of Medicine in St. Louis have genetically modified astrocytes in vivo to express chimeric antigen receptors (CARs) that recognize and phagocytose Aβ plaques. http://www.bioworld.com/articles/729411 Mon, 09 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729411-synthetic-peptide-and-car-a-each-clear-amyloid-in-alzheimers Illustration of amyloid plaques on neurons The K-health MIRAE Initiative, also known as Korean ARPA-H, announced plans to allocate about ₩162 billion (US$110 million) in nine new projects over the next five years, with a focus on strengthening national health security. http://www.bioworld.com/articles/729359 Fri, 06 Mar 2026 12:00:00 -0500 https://www.bioworld.com/articles/729359-korean-arpa-h-to-invest-162b-in-nine-projects-in-2026 Korea ARPA-H roundtable K-health MIRAE Initiative Director General Sun Kyung, center, and project managers at a roundtable meeting in Seoul, South Korea on March 5. The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral therapy. At the Conference on Retroviruses and Opportunistic Infections (CROI) held Feb. 22-25, 2026, in Denver, the scientific community examined how the virus affects the brain, how the reservoir is established in the CNS, and which genetic, immunological or treatment-related factors influence cognitive health. http://www.bioworld.com/articles/729051 Thu, 26 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/729051-croi-2026-highlights-depression-and-cognitive-vulnerability-in-hiv Depression concept with human, broken brain and heavy rain Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many of them are aging in good health. However, others present symptoms of cognitive decline. HIV can reach the brain and establish a reservoir there. Yet, it is still unknown what this reservoir is like, which cells are affected, and which comorbidities are typical of aging or are associated with the virus. http://www.bioworld.com/articles/729031 Wed, 25 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/729031-croi-2026-neurodegeneration-the-challenge-of-aging-with-hiv Brain and virus with chromosome Innovacell Inc. launched a ¥14.16 billion (US$91.2 million) stock sale on the Tokyo Stock Exchange Feb. 24, ending a near two-year lull of biotech listings in Japan while signaling a dynamic year ahead for cell-based therapeutics. http://www.bioworld.com/articles/729194 Tue, 24 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/729194-innovacells-91m-tokyo-ipo-to-fund-incontinence-cell-therapies Glass yen/yuan symbol Japan is backing conditional approvals of Amchepry (raguneprocel, Sumitomo Pharma Co. Ltd./Racthera Co. Ltd.) and Reheart (Cuorips Inc.), positioning them to become the world’s first induced pluripotent stem cell-derived (iPSC) therapies to receive regulatory clearance. http://www.bioworld.com/articles/729235 Tue, 24 Feb 2026 11:00:00 -0500 https://www.bioworld.com/articles/729235-japan-endorses-two-ipsc-drugs-for-approval-under-cea-pathway Stem cells Japan is backing conditional approvals of Amchepry (raguneprocel, Sumitomo Pharma Co. Ltd./Racthera Co. Ltd.) and Reheart (Cuorips Inc.), positioning them to become the world’s first induced pluripotent stem cell-derived (iPSC) therapies to receive regulatory clearance. http://www.bioworld.com/articles/729099 Fri, 20 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/729099-japan-endorses-two-ipsc-drugs-for-approval-under-cea-pathway Stem cells Building on the foundation laid in 2020, researchers at the University of California, San Francisco (UCSF) have now shown that targeting the GPI-anchored vascular enzyme TNAP can reproduce the cognitive benefits previously attributed to the liver-derived exercise factor GLPD1. http://www.bioworld.com/articles/728933 Thu, 19 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728933-a-closer-look-at-how-the-liver-rejuvenates-the-aging-brain Mouse on treadwheel Med-tech companies with an AI component in their solutions will certainly find investors willing to back them. AI after all, is being used to develop more effective, smarter technologies. However, investors will only deploy capital into innovations that address genuine clinical needs. The aging population is driving interest in devices targeting cardiovascular and musculoskeletal disorders, and other solutions geared toward neurological conditions, women’s health and diagnostics are also attracting investor attention. http://www.bioworld.com/articles/729072 Wed, 18 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/729072-ai-transforming-med-tech-in-2026-clinical-need-drives-investments AI medical illustration